Gregory A. Grabowski

Synageva BioPharma Corp. is a biopharmaceutical company which focuses on the discovery, development, and commercialization of therapeutic products for patients with life-threatening rare diseases and high unmet medical need. The company is currently evaluating sebelipase alfa in global clinical trials for LAL Deficiency, a lysosomal storage disease associated with liver damage and accelerated atherosclerosis in children and adults, and in infants, premature death often before six months of age. Synageva BioPharma was founded in 1993 and is headquartered in Lexington, MA.

ThinkGenetic, Inc. provides artificial intelligence solutions for diagnosed and undiagnosed genetic diseases. The company is based in Waynesboro, VA. The company was founded by Dawn Jacob Laney, Dave Jacob, Len Barker. Dave Jacob has been the CEO since incorporation.